Navigation Links
Insmed to Present at Collins Stewart Fourth Annual Growth Conference
Date:7/9/2008

RICHMOND, Va., July 9 /PRNewswire-FirstCall/ -- Insmed Inc. (Nasdaq: INSM), a developer of follow-on biologics and biopharmaceuticals, announced today that Steve Glover, President Insmed Therapeutics, will present at the Collins Stewart Fourth Annual Growth Conference on Thursday, July 10, 2008 at 10:30 AM ET, in New York.

The conference will take place at the Mandarin Oriental Hotel in New York City, from Tuesday, July 8 through Thursday, July 10. Insmed's presentation will be webcast live over the Internet and can be accessed directly on http://www.wsw.com/webcast/clst/insm/. The webcast will be archived for a period of 90 days.

About Insmed

Insmed Inc. is a biopharmaceutical company with unique protein process development and manufacturing experience and a proprietary protein platform aimed at niche markets with unmet medical needs. For more information, please visit http://www.insmed.com.

Forward-Looking Statements

This release contains forward-looking statements which are made pursuant to provisions of Section 21E of the Securities Exchange Act of 1934. Investors are cautioned that such statements in this release, including statements relating to planned clinical study design, regulatory and business strategies, plans and objectives of management and growth opportunities for existing or proposed products, constitute forward-looking statements which involve risks and uncertainties that could cause actual results to differ materially from those anticipated by the forward-looking statements. The risks and uncertainties include, without limitation, risks that product candidates may fail in the clinic or may not be successfully marketed or manufactured, we may lack financial resources to complete development of product candidates, the FDA may interpret the results of studies differently than us, competing products may be more successful, demand for new pharmaceutical products may decrease, the biopharmaceutical industry may experience negative market trends, our entrance into the follow on biologics market may be unsuccessful, our common stock could be delisted from the Nasdaq Capital Market and other risks and challenges detailed in our filings with the U.S. Securities and Exchange Commission, including our Annual Report on Form 10-K for the year ended December 31, 2007. Readers are cautioned not to place undue reliance on any forward-looking statements which speak only as of the date of this release. We undertake no obligation to publicly release the results of any revisions to these forward-looking statements that may be made to reflect events or circumstances that occur after the date of this release or to reflect the occurrence of unanticipated events.

Investor Relations Contact:

Brian Ritchie - FD

212-850-5683

brian.ritchie@fd.com

Corporate Communications Contact:

John Procter - Gibraltar Associates

202-879-5808

jprocter@gibraltar-llc.com


'/>"/>
SOURCE Insmed Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Insmed to Request Hearing Before NASDAQ Panel to Review NASDAQ Staff Determination
2. Insmed Announces First Quarter 2008 Financial Results
3. Insmed to Present at CBI Follow-On Biologics Conference
4. Insmed Selected to Complete Congressional Questionnaire Regarding the Potential Establishment of a Follow-On Biologics Regulatory Pathway
5. Insmed Announces Additional Information in Compliance With NASDAQ Rules
6. Insmed Announces Fourth Quarter and Full-Year 2007 Financial Results
7. Insmed Announces Listing Transfer from Nasdaq Global Market to Nasdaq Capital Market
8. Insmed to Host Fourth Quarter and Full-Year 2007 Conference Call
9. Insmed CEO Issues Statement on White House FY09 Budget and FDA Statements on Follow-On Biologics
10. Insmed President Interviewed for Follow-On Biologics Podcast: Insmed Inc. President Steve Glover Discusses Safe and Effective Biologic Therapies and Reduced Costs with The American Magazine
11. Insmed to Appeal Delisting Notification From Nasdaq
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/10/2017)... , ... October 10, 2017 , ... ... and business process optimization firm for the life sciences and healthcare industries, announces ... conference in San Francisco. , The presentation, “Automating GxP Validation for Agile Cloud ...
(Date:10/9/2017)... Oct. 9, 2017  BioTech Holdings announced today ... which its ProCell stem cell therapy prevents limb ... The Company, demonstrated that treatment with ProCell resulted ... saved as compared to standard bone marrow stem ... resulted in reduction of therapeutic effect.  ...
(Date:10/9/2017)... Charlotte, N.C. (PRWEB) , ... October 09, 2017 , ... ... Purple announced Dr. Christopher Stubbs, a professor in Harvard University’s Departments of Physics and ... Dr. Stubbs was a member of the winning team for the 2015 Breakthrough Prize ...
(Date:10/9/2017)... ... October 09, 2017 , ... ... the medical journal, Epilepsia, Brain Sentinel’s SPEAC® System which uses the surface ... detecting generalized tonic-clonic seizures (GTCS) using surface electromyography (sEMG). The prospective multicenter ...
Breaking Biology Technology:
(Date:3/29/2017)... , March 29, 2017  higi, the health ... in North America , today announced ... and the acquisition of EveryMove. The new investment and ... set of tools to transform population health activities through ... lifestyle data. higi collects and secures data ...
(Date:3/24/2017)... , March 24, 2017 The Controller General of ... Mr. Abdulla Algeen have received the prestigious international IAIR Award ... Continue Reading ... ... and Deputy Controller Abdulla Algeen (small picture on the right) have received ...
(Date:3/23/2017)... 2017 Research and Markets has announced the ... Trends - Industry Forecast to 2025" report to their offering. ... The Global ... of around 8.8% over the next decade to reach approximately $14.21 ... market estimates and forecasts for all the given segments on global ...
Breaking Biology News(10 mins):